Anti TNF α Improves Endothelial Dysfunction in IBD Patients

NCT01881464 UNKNOWN

Study hypothesis - this study will assess the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.

Details

Lead sponsor	Carmel Medical Center
Status	UNKNOWN
Enrolment	20
Start date	2014-05
Completion	2018-06

Conditions

• Crohn's Disease

Interventions

• Endopath from Itamar medical - FDA approved device.
• Anti TNF Alfa.

Primary outcomes

• This study will assessed the presence of endothelial dysfunction in patients, C with crohn's disease before and after 12 weeks treatment of anti TNF α. CDAI, CRP. — 12 month
  In this study we will preformed an endothelial function test before and after 12 weeks of treatment, by Endopath device from Itamar medical, FDA approved. Endo-PAT tests can be carried out in both the office and hospital settings, with patients positioned either sitting or supine. Endo-PAT bio-sensors are placed on the index fingers of both arms. The test takes 15 minutes to complete, is very easy to perform, and is both operator and interpreter independent. Thermo-neutral, quiet surroundings are recommended. Endo-PAT quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff).

Countries

Israel